pharmaceuticals

Pharmacy-benefit managers (PBMs) have been scrutinized for their role in drug distribution for years. Now a bipartisan group of lawmakers is threatening to break up the companies behind these so-called drug middlemen. What To Know: According to a Wall Street Journal report, Sen. Elizabeth Warren (D...

Eli Lilly and Co (NYSE:LLY) is making headlines with its $15 billion share buyback plan and a 15% dividend boost. Yet, as the Indianapolis-based pharma giant enjoys the success of blockbuster drugs like Mounjaro and Zepbound, its stock is sending mixed technical signals ahead of its next move. Eli...

Shares of Eli Lilly and Company (NYSE:LLY) are trading higher on Wednesday. The company said that its Zepbound drug was more effective in helping adults with obesity lose weight than Novo Nordisk A/S's (NYSE:NVO) Wegovy. It cited data from a phase 3b trial. But the rally may be short-lived. This is...

Bristol-Myers Squibb Co (NYSE:BMY) filed a lawsuit on Tuesday against the U.S. Health Resources and Services Administration (HRSA) and the U.S. Department of Health and Human Services (HHS), alleging that HRSA's rejection of its proposed rebate model for the 340B Drug Pricing Program violates...

On Wednesday, Verge Genomics announced that Eli Lilly And Co (NYSE:LLY) has opted to pursue the development of therapeutics against two validated drug targets for amyotrophic lateral sclerosis (ALS) as part of the companies’ collaboration, which was initiated in July 2021. Amyotrophic...

Pfizer Inc. (NYSE:PFE) shares are lower on Thursday due to news that President-elect Donald Trump picked Robert F. Kennedy Jr. as his next secretary of the Department of Health and Human Services. This has some investors concerned because Kennedy was critical of certain vaccines and vaccinations....

AC Immune SA (NASDAQ:ACIU) revealed data from a Phase 2 clinical trial of its wholly owned anti-alpha-synuclein (a-syn) active immunotherapy candidate for early Parkinson’s disease. Dr. Andrea Pfeifer, CEO of AC Immune, commented: “The level of immunogenicity after only 3 months of...

AstraZeneca plc (NASDAQ:AZN) is set to report its third-quarter 2024 earnings Tuesday morning, and the company's second-quarter performance hints at robust growth fueled by its oncology and cardiovascular portfolios. What To Know: In the second quarter, AstraZeneca reported $12.94 billion in...

On Monday, Rapt Therapeutics, Inc. (NASDAQ:RAPT) stock is trading lower after the company announced it was terminating its zelnecirnon (RPT193) program. Zelnecirnon was being evaluated in two randomized, placebo-controlled Phase 2 clinical trials in asthma and atopic dermatitis (AD). Both trials...

On Monday, AbbVie Inc (NYSE:ABBV) stock is trading lower after it released data from its two Phase 2 EMPOWER trials of emraclidine for schizophrenia. The trials investigating emraclidine as a once-daily, oral monotherapy treatment for adults with schizophrenia. The patients experienced an...

Teva Pharmaceutical Industries Ltd (NYSE:TEVA) reported third-quarter 2024 sales of $4.33 billion on Wednesday. It beat the consensus of $4.12 billion. Revenues increased 13% year-over-year and 15% on constant currency. This was mainly due to higher revenues from generic products in all segments (i...

New On The Block Altus Power (NYSE:AMPS) tapped investment bank Moelis & Company LLC to explore strategies to boost shareholder value. According to the clean electricity provider, the process should wrap up by 2025. Altus retained law firm Latham & Watkins to advise on legal matters....

Enanta Pharmaceuticals Inc. (NASDAQ:ENTA) released on Thursday topline results from a Phase 2a human challenge study of EDP-323 in healthy adults infected with respiratory syncytial virus (RSV). The data demonstrated that EDP-323 was generally safe and well-tolerated and achieved an 85%-87%...

Eli Lilly And Co (NYSE:MRK) revealed new long-term results on Wednesday, showing promise for treatment in patients with moderate-to-severe atopic dermatitis. What Happened: The company’s data for the ADjoin long-term extension study of Ebglyss (EHB-glihs) will be presented at the European...

Piper Sandler initiated coverage on Abbott Laboratories (NYSE:ABT), noting the company as a versatile large-cap with an attractive valuation. Abbott has a diversified business model with solid distribution across segments (medtech, diagnostics, nutrition, pharmaceuticals) and geography. Medical...